Bioxytran Reports Positive ProLectin-M Phase 1b/2a COVID Trial

Bioxytran ( (BIXT) ) has shared an update.

On March 2, 2026, Bioxytran, Inc. reported positive results from a randomized, double-blind, placebo-controlled Phase 1b/2a trial of its oral antiviral ProLectin-M in 39 hospitalized patients in India with mild to moderate COVID-19. The galectin-targeting, carbohydrate-based drug is being developed as a broad-range antiviral that acts on host–virus interactions rather than intracellular viral replication.

The highest tested dose of ProLectin-M, 16,800 mg per day plus standard of care, achieved 90% viral clearance and 90% two-point clinical improvement on the WHO Ordinal Scale by Day 5, compared with 20% viral clearance in the placebo arm, with all groups reaching viral clearance by Day 7. No serious adverse events, treatment-related discontinuations, or clinically meaningful safety signals were observed, underscoring a favorable tolerability profile that supports continued clinical development and potentially strengthens Bioxytran’s position in the evolving antiviral therapeutics landscape.

More about Bioxytran

Bioxytran, Inc. is a clinical-stage biotechnology company focused on developing novel carbohydrate-based therapeutics to address significant unmet medical needs in infectious and cardiovascular diseases. Its lead investigational drug, ProLectin-M, is an oral antiviral designed to target galectins, carbohydrate-binding proteins involved in viral attachment and entry into host cells, offering a differentiated, host-directed strategy that may be applicable across multiple viral infections.

ProLectin-M is being advanced under an active U.S. Investigational New Drug framework and international regulatory oversight, leveraging carbohydrate chemistry to block viral entry mechanisms mediated by galectin interactions. The company’s pipeline positions it within the broader antiviral and cardiovascular treatment markets, where there is ongoing demand for new mechanisms of action and improved safety profiles.

Average Trading Volume: 189,865

Technical Sentiment Signal: Sell

Current Market Cap: $4.45M

For detailed information about BIXT stock, go to TipRanks’ Stock Analysis page.